First-Line Tecentriq Tops Chemo in PD-L1-High NSCLC

(MedPage Today) -- Patients with metastatic non-small cell lung cancer (NSCLC) with high PD-LI expression achieved longer survival when treated with atezolizumab (Tecentriq) than those treated with platinum-based chemotherapy, researchers found...